# ASX Announcement

18/06/2021

emyria
myriad data.
individual care.

## Results of GM

**Emyria Limited (ASX: EMD)** (Emyria or the Company), a drug development and clinical services company, advises that General Meeting of shareholders was held today, 18 June 2021. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

### Poll Results

| Resolutions | | For | Against | Abstain |
|---|---|---|---|---|
| 1a | Ratification of prior issue of Placement Shares – Listing Rule 7.1 | 74,107,128 | 610,000 | 87,200 |
| 1b | Ratification of prior issue of Placement Shares – Listing Rule 7.1A | 74,107,127 | 610,000 | 87,201 |
| 2 | Ratification of prior issue of Placement Options | 74,856,413 | 615,000 | 97,201 |
| 3 | Ratification of prior issue of Lead Manager Options to Sixty Two Capital Pty Ltd | 74,515,824 | 615,000 | 437,790 |
| 4 | Ratification of prior issue of Consultant Options to Dr Karen Smith | 74,631,829 | 510,000 | 426,745 |

## Proxy Votes Received

| Resolutions | | For | Against | At Proxy Holders Discretion | Abstain |
|---|---|---|---|---|---|
| 1a | Ratification of prior issue of Placement Shares – Listing Rule 7.1 | 53,175,140 | 610,000 | 6,289 | 87,200 |
| 1b | Ratification of prior issue of Placement Shares – Listing Rule 7.1A | 53,175,139 | 610,000 | 6,289 | 87,201 |
| 2 | Ratification of prior issue of Placement Options | 53,924,425 | 615,000 | 6,289 | 97,201 |
| 3 | Ratification of prior issue of Lead Manager Options to Sixty Two Capital Pty Ltd | 53,583,836 | 615,000 | 6,289 | 437,790 |
| 4 | Ratification of prior issue of Consultant Options to Dr Karen Smith | 53,699,881 | 510,000 | 6,289 | 426,745 |

Release authorised by:

Simon Robertson
Company Secretary

---

For further information on **Emyria**:


**Dr Michael Winlo**
**Managing Director**
**(08) 6559 2800**
**mwinlo@emyria.com**

**Lexi O'Halloran**
**Investor Relations**
**+ 61 (0) 404 577 076**
**lexi@janemorganmanagement.com.au**

**Andrew Williams**
**Media Relations**
**+61 (0) 412 614 125**
**andreww@profilemedia.com.au**

## About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. **Emyria's Treatments** target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - www.emeraldclinics.com.au)

**Emyria Data** provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Emyria's first drug development program, **EMD-003** is targeting unmet needs in mental health. Specifically psychological distress and the symptoms of anxiety, depression and stress.

Emyria's second drug development program, **EMD-004** is targeting symptoms related to Irritable Bowel Syndrome (IBS).

Emyria is also leading the development of psychedelic-assisted therapy program with the the launch of **EMDMA-001**, an MDMA-assisted psychotherapy program for patients with Post-Traumatic Stress Disorder (PTSD).

---

### Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.